{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:36:18Z","timestamp":1792089378564,"version":"4.4.0"},"reference-count":26,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["SJU"],"abstract":"<jats:p>Objective: To evaluate clinical outcome and complications of prostate artery embolization (PAE) in Iceland, using the International Prostate Symptom Score (IPSS), quality of life (QoL) and catheter freedom to measure clinical success.\nMaterials and methods: Retrospective single-center study, including patients who underwent PAE from August 2019 to February 2024 due to benign prostatic hyperplasia (BPH). Patients completed a questionnaire on lower urinary tract symptoms (LUTS), QoL, catheter status and use of medication. All additional data were retrieved from the medical records.\u00a0\nResults: A total of 34 patients were included, with a mean age of 75 during PAE and a technical success rate of 91%. Patients had significant clinical improvement, with a mean reduction in IPSS score from 20.0 to 9.0 (p &lt; 0.001) and QoL score from 5.5 to 1.8 (p &lt; 0.001). PAE also resulted in a 69% reduction (p &lt; 0.001) in urinary catheter dependency. Post-PAE complications were uncommon (3\/34) and all resolved without long-term effects.\nConclusion: PAE is an effective and safe treatment option for LUTS and\/or urinary retention in men with BPH, offering catheter freedom and significant improvement in urological symptoms and quality of life.<\/jats:p>","DOI":"10.2340\/sju.v60.44137","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T07:42:02Z","timestamp":1752133322000},"page":"130-134","source":"Crossref","is-referenced-by-count":2,"title":["Prostate artery embolization for benign prostatic hyperplasia: a retrospective single-center study of clinical outcome"],"prefix":"10.2340","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5898-1271","authenticated-orcid":false,"given":"Jon","family":"Bjarnason","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann Pall","family":"Ingimarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hjalti","family":"Thorisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristbjorn","family":"Reynisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon Orn","family":"Fridriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baldvin Thorkell","family":"Kristjansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Bazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"116516","doi-asserted-by":"crossref","unstructured":"Lee CL, Kuo HC. Pathophysiology of benign prostate enlargement and lower urinary tract symptoms: Current concepts. Tzu Chi Med J. 2017;29(2):79\u201383. https:\/\/doi.org\/10.4103\/tcmj.tcmj_20_17","DOI":"10.4103\/tcmj.tcmj_20_17"},{"key":"116517","doi-asserted-by":"crossref","unstructured":"Naidu SG, Narayanan H, Saini G, et al. Prostate artery embolization-review of indications, patient selection, techniques and results. J Clin Med. 2021;10(21). https:\/\/doi.org\/10.3390\/jcm10215139","DOI":"10.3390\/jcm10215139"},{"key":"116518","doi-asserted-by":"crossref","unstructured":"Davis C, Golzarian J, White S, et al. Development of research agenda in prostate artery embolization: summary of society of interventional radiology consensus panel. J Vasc Interv Radiol. 2020;31(1):108\u2013113. https:\/\/doi.org\/10.1016\/j.jvir.2019.09.019","DOI":"10.1016\/j.jvir.2019.09.019"},{"key":"116519","doi-asserted-by":"crossref","unstructured":"Fujimura T, Kume H, Nishimatsu H, et al. Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom score. BJU Int. 2012;109(10):1512\u20131516. https:\/\/doi.org\/10.1111\/j.1464-410X.2011.10445.x","DOI":"10.1111\/j.1464-410X.2011.10445.x"},{"key":"116520","doi-asserted-by":"crossref","unstructured":"Majbar E, Swanberg J, Alamdari F, et al. Early experience of prostate artery embolization: a retrospective single-centre study. Scand J Urol. 2025;60:1\u20137. https:\/\/doi.org\/10.2340\/sju.v60.42495","DOI":"10.2340\/sju.v60.42495"},{"key":"116521","doi-asserted-by":"crossref","unstructured":"Bhatia A, Porto JG, Maini A, et al. One-year outcomes after prostate artery embolization versus laser enucleation: a network meta-analysis. BJUI Compass. 2024;5(2):189\u2013206. https:\/\/doi.org\/10.1002\/bco2.302","DOI":"10.1002\/bco2.302"},{"key":"116522","doi-asserted-by":"crossref","unstructured":"Stenmark F, Brudin L, Kj\u00f6lhede H, et al. Treatment with CoreTherm in 570 patients with prostate volumes of 80\u2013366 ml: an evaluation of short- and long-term retreatment risk. Scand J Urol. 2022;56(4):336\u2013341. https:\/\/doi.org\/10.1080\/21681805.2022.2108139","DOI":"10.1080\/21681805.2022.2108139"},{"key":"116523","doi-asserted-by":"crossref","unstructured":"Arch A, Thamsborg A, Winck-Flyvholm L, et al. Thermo-expandable intraprostatic nitinol stents in the treatment of bladder outlet obstruction: a consecutive case series. Scand J Urol. 2024;59:169\u2013172. https:\/\/doi.org\/10.2340\/sju.v59.41991","DOI":"10.2340\/sju.v59.41991"},{"key":"116524","doi-asserted-by":"crossref","unstructured":"Salmivalli A, Bostr\u00f6m P, Nurminen P, et al. National trends of surgery for benign prostatic hyperplasia in Finland. Scand J Urol. 2024;59:70\u201375. https:\/\/doi.org\/10.2340\/sju.v59.32425","DOI":"10.2340\/sju.v59.32425"},{"key":"116525","doi-asserted-by":"crossref","unstructured":"Stenmark F, Brundin L, Gunnarsson O, et al. A randomised study of TURP after intraprostatic injection of mepicacaine\/adrenaline versus regular TURP in patients with LUTS\/BPO. Scand J Urol. 2023;58:46\u201351. https:\/\/doi.org\/10.2340\/sju.v58.7798","DOI":"10.2340\/sju.v58.7798"},{"key":"116526","doi-asserted-by":"crossref","unstructured":"Carnevale FC, Antunes AA, da Motta Leal Filho JM, et al. Prostatic artery embolization as a primary treatment for benign prostatic hyperplasia: preliminary results in two patients. Cardiovasc Intervent Radiol. 2010;33(2):355\u2013361. https:\/\/doi.org\/10.1007\/s00270-009-9727-z","DOI":"10.1007\/s00270-009-9727-z"},{"key":"116527","doi-asserted-by":"crossref","unstructured":"Yu H, Isaacson AJ, Burke CT. Review of current literature for prostatic artery embolization. Semin Intervent Radiol. 2016;33(3):231\u2013235. https:\/\/doi.org\/10.1055\/s-0036-1586141","DOI":"10.1055\/s-0036-1586141"},{"key":"116528","doi-asserted-by":"crossref","unstructured":"Elkoushy MA, Elhilali MM. Management of benign prostatic hyperplasia larger than 100 ml: simple open enucleation versus transurethral laser prostatectomy. Curr Urol Rep. 2016;17(6):44. https:\/\/doi.org\/10.1007\/s11934-016-0601-7","DOI":"10.1007\/s11934-016-0601-7"},{"key":"116529","doi-asserted-by":"crossref","unstructured":"Xiang P, Guan D, Du Z, et al. Efficacy and safety of prostatic artery embolization for benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials. Eur Radiol. 2021;31(7):4929\u20134946. https:\/\/doi.org\/10.1007\/s00330-020-07663-2","DOI":"10.1007\/s00330-020-07663-2"},{"key":"116530","doi-asserted-by":"crossref","unstructured":"Sw\u00e4rd J, Bohlin K, Henrikson O, et al. Long-term efficacy of selective arterial embolisation of renal angiomyolipoma. Scand J Urol. 2023;58:86\u201392. https:\/\/doi.org\/10.2340\/sju.v58.12318","DOI":"10.2340\/sju.v58.12318"},{"key":"116531","doi-asserted-by":"crossref","unstructured":"Dias US, Jr, de Moura MRL, et al. Prostatic artery embolization: indications, preparation, techniques, imaging evaluation, reporting, and complications. Radiographics. 2021;41(5):1509\u20131530. https:\/\/doi.org\/10.1148\/rg.2021200144","DOI":"10.1148\/rg.2021200144"},{"key":"116532","doi-asserted-by":"crossref","unstructured":"Lindgren H, Bl\u00e4ckberg M. Introduction of prostate artery embolization (PAE) in Sweden. Scand J Urol. 2019;53(2\u20133):151\u2013155. https:\/\/doi.org\/10.1080\/21681805.2019.1610494","DOI":"10.1080\/21681805.2019.1610494"},{"key":"116533","doi-asserted-by":"crossref","unstructured":"Kuang M, Vu A, Athreya S. A systematic review of prostatic artery embolization in the treatment of symptomatic benign prostatic hyperplasia. Cardiovasc Intervent Radiol. 2017;40(5):655\u2013663. https:\/\/doi.org\/10.1007\/s00270-016-1539-3","DOI":"10.1007\/s00270-016-1539-3"},{"key":"116534","doi-asserted-by":"crossref","unstructured":"Leng B, Zhou CG, Liu S, et al. Prostatic artery embolization to achieve freedom from catheterization in patients with acute urinary retention caused by benign prostatic hyperplasia. J Vasc Interv Radiol. 2021;32(7):1062\u20131067. https:\/\/doi.org\/10.1016\/j.jvir.2021.03.530","DOI":"10.1016\/j.jvir.2021.03.530"},{"key":"116535","doi-asserted-by":"crossref","unstructured":"Pisco JM, Bilhim T, Pinheiro LC, et al. Medium- and long-term outcome of prostate artery embolization for patients with benign prostatic hyperplasia: results in 630 patients. J Vasc Interv Radiol. 2016;27(8):1115\u20131122. https:\/\/doi.org\/10.1016\/j.jvir.2016.04.001","DOI":"10.1016\/j.jvir.2016.04.001"},{"key":"116536","doi-asserted-by":"crossref","unstructured":"Bilhim T, Costa NV, Torres D, et al. Long-term outcome of prostatic artery embolization for patients with benign prostatic hyperplasia: single-centre retrospective study in 1072 patients over a 10-year period. Cardiovasc Intervent Radiol. 2022;45(9):1324\u20131336. https:\/\/doi.org\/10.1007\/s00270-022-03199-8","DOI":"10.1007\/s00270-022-03199-8"},{"key":"116537","doi-asserted-by":"crossref","unstructured":"Wang XY, Chai YM, Huang WH, et al. Prostate artery embolization on lower urinary tract symptoms related to benign prostatic hyperplasia: a systematic review and meta-analysis. World J Clin Cases. 2022;10(32):11812\u201311826. https:\/\/doi.org\/10.12998\/wjcc.v10.i32.11812","DOI":"10.12998\/wjcc.v10.i32.11812"},{"key":"116538","doi-asserted-by":"crossref","unstructured":"Insausti I, Galbete A, Lucas-Cava V, et al. Prostatic Artery Embolization (PAE) using polyethylene glycol microspheres: safety and efficacy in 81 patients. Cardiovasc Intervent Radiol. 2022;45(9):1339\u20131348. https:\/\/doi.org\/10.1007\/s00270-022-03165-4","DOI":"10.1007\/s00270-022-03165-4"},{"key":"116539","doi-asserted-by":"crossref","unstructured":"Xu ZW, Zhou CG, Tian W, et al. Long-term efficacy and recurrence prediction of prostatic artery embolization for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Cardiovasc Intervent Radiol. 2022;45(12):1801\u20131809. https:\/\/doi.org\/10.1007\/s00270-022-03272-2","DOI":"10.1007\/s00270-022-03272-2"},{"key":"116540","doi-asserted-by":"crossref","unstructured":"Svarc P, Taudorf M, Nielsen MB, et al. Postembolization syndrome after prostatic artery embolization: a systematic review. Diagnostics (Basel). 2020;10(9). https:\/\/doi.org\/10.3390\/diagnostics10090659","DOI":"10.3390\/diagnostics10090659"},{"key":"116541","doi-asserted-by":"crossref","unstructured":"Shuka N, Hasimi E, Kristo A, et al. Contrast-induced nephropathy in interventional cardiology: incidence, risk factors, and identification of high-risk patients. Cureus. 2023;15(12):e51283. https:\/\/doi.org\/10.7759\/cureus.51283","DOI":"10.7759\/cureus.51283"}],"container-title":["Scandinavian Journal of Urology"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/44137\/50705","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/44137\/50705","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T07:42:12Z","timestamp":1752133332000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/view\/44137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":26,"URL":"https:\/\/doi.org\/10.2340\/sju.v60.44137","relation":{},"ISSN":["2168-1813"],"issn-type":[{"value":"2168-1813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]}}}